US2005226940A1PendingUtilityA1

Antitumour compositions containing taxane derivatives

61
Assignee: AVENTIS PHARMA SAPriority: Nov 10, 1992Filed: Jun 10, 2005Published: Oct 13, 2005
Est. expiryNov 10, 2012(expired)· nominal 20-yr term from priority
Inventors:Marie-Christine Bissery
A61P 35/02A61P 35/00A61K 38/21A61K 31/66A61K 38/50A61K 31/7048C12Y 305/01001A61K 31/4745A61K 45/06A61K 38/20C07D 305/14A61K 31/675A61K 31/525A61K 31/7072A61K 31/505A61K 31/337A61K 31/335A61K 33/243
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antitumour combinations consisting of taxol or Taxotère or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled)  
   
   
       15 . A method of treating a neoplastic disease in a patient in need thereof, comprising administering to the patient 
 an effective amount of at least one taxane chosen from taxol, docetaxel, and derivatives thereof, and    an effective amount of at least one topoisomerase inhibitor chosen from camptothecin, CPT-11, topotecan, and pyridobenzoindole,    wherein the at least one taxane and at least one topoisomerase inhibitor exhibit therapeutic synergy.    
   
   
       16 . The method of  claim 15 , wherein the effective amount of the at least one taxane is not greater than the maximum tolerated dose of the at least one taxane.  
   
   
       17 . The method of  claim 15 , wherein the effective amount of the at least one topoisomerase inhibitor is not greater than the maximum tolerated dose of the at least one topoisomerase inhibitor.  
   
   
       18 . The method of  claim 15 , wherein the at least one topoisomerase inhibitor comprises camptothecin.  
   
   
       19 . The method of  claim 15 , wherein the at least one topoisomerase inhibitor comprises CPT-11.  
   
   
       20 . The method of  claim 15 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered simultaneously.  
   
   
       21 . The method of  claim 15 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and simultaneously.  
   
   
       22 . The method of  claim 15 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and sequentially.  
   
   
       23 . The method of  claim 19 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and sequentially.  
   
   
       24 . The method of  claim 19 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered simultaneously.  
   
   
       25 . The method of  claim 19 , wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and simultaneously.

Join the waitlist — get patent alerts

Track US2005226940A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.